Green Journals

International Approved Journals

Journal Information

Journal Title	Urologic Oncology: Seminars and Original Investigations
Publisher	Elsevier Inc.
ISSN	1078-1439
E-ISSN	1873-2496
Database	SCOPUS
Domain	Health Sciences, Life Sciences, Physical Sciences, Social Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Adoption and perceptions of utility of the RENAL nephrometry score among fellowship-trained urologic oncologists in North America
2026-11
Authors: Keenan Moore, Matthew Driscoll, Paige Wallner et al.
DOI: 10.1016/j.urolonc.2026.10.006

Diagnostic value of CEUS-VI-RADS for predicting muscle invasion in bladder cancer: Validation of the scoring system and introduction of tumor-bladder wall contact length as a supplementary quantitative metric
2026-11 Vol. 44 Issue 11 Pages 859-865
Authors: Wenhao Qu, Ju Zhu, Yahan Yang et al.
DOI: 10.1016/j.urolonc.2026.08.023

Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy
2026-11 Vol. 44 Issue 11 Pages 960-967
Authors: Todd M. Morgan, Ching-Yu Wang, Halit O. Yapici et al.
DOI: 10.1016/j.urolonc.2026.08.016

Association of robot-assisted radical prostatectomy with improved oncological outcomes in patients with oligometastatic prostate cancer: A multicenter exploratory study in China
2026-11 Vol. 44 Issue 11 Pages 921-930
Authors: Yujie Dong, Zhen Tian, Weilin Chen et al.
DOI: 10.1016/j.urolonc.2026.08.025

Novel use of computed tomography-derived body composition to facilitate risk assessment in patients with bladder cancer
2026-11 Vol. 44 Issue 11 Pages 946-959
Authors: Lea Mantz, Alex Zhu, Nathaniel D Mercaldo et al.
DOI: 10.1016/j.urolonc.2026.08.013

Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis
2026-11 Vol. 44 Issue 11 Pages 866-872
Authors: James R. Janopaul-Naylor, Dattatraya Patil, Nikhil T. Sebastian et al.
DOI: 10.1016/j.urolonc.2026.08.014

Adherence to active surveillance monitoring among Medicare beneficiaries with prostate cancer
2026-11
Authors: Jiaye Shen, Aaron J. Katz, Yahui Xie et al.
DOI: 10.1016/j.urolonc.2026.10.008

Retraction notice to “Combination Chemotherapy with Docetaxel, Estramustine and Suramin for Hormone Refractory Prostate Cancer” [Urologic Oncology: Seminars and Original Investigations 23 (2005) 93–101]
2026-11
Authors: Mohammad Reza Safarinejad
DOI: 10.1016/j.urolonc.2026.10.002

Molecular profiling of renal mass biopsy tissue: A review of feasibility and clinical utility
2026-11
Authors: Joseph McGrath, Robert Willis, Akash Sridhar et al.
DOI: 10.1016/j.urolonc.2026.10.007

The AURKA–PTTG1 signaling axis induces enzalutamide resistance in prostate cancer
2026-11 Vol. 44 Issue 11 Pages 897-910
Authors: Guangye Han, Zhenhui Li, Weihang Song et al.
DOI: 10.1016/j.urolonc.2026.08.010